ESC 2017
Apixaban Compared to Standard Care in NVAF Patients Undergoing Cardioversion
This is an investigational use for Eliquis.
Your search for apixaban returned 102 results
News
Intracranial Bleed Risk Compared for Apixaban, Warfarin in A-fib Patients
Patients taking apixaban showed significantly less intracranial hemorrhage (0.33% per year) vs. patients taking warfarin (0.80% per year) no matter the type and location.
News
Is Apixaban an Appropriate Alternative to Warfarin in Patients with Severe Renal Impairment?
Findings from a study published in the British Journal of Clinical Pharmacology showed that apixaban appeared to be an appropriate alternative to warfarin for patients with severe renal impairment.
News
Apixaban Dosing Examined in Patients With Only One-Dose Reduction Criterion
For patients in the Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) trial, the 5 mg twice daily dose of apixaban is beneficial and appropriate for those with one dose-reduction criterion, according to a study published online in JAMA Cardiology.
AHA 2015
Apixaban Efficacy, Safety Evaluated in AF Patient on Multiple Concomitant Medications
Older patients, females, and those with comorbidities were more likely to be on multiple medications.
AHA 2015
Apixaban vs. Warfarin: Effects Compared in AF Patients With, Without PAD
Researchers conducted a post hoc analysis of the ARISTOTLE trial which included patients with atrial fibrillation (AF) and a risk of stroke treated with either apixaban or warfarin for the prevention of stroke/ systemic embolism.
News
Can Education Boost Adherence to Apixaban? New Data Presented
Research presented at the European Society of Cardiology Congress 2015 reports that an education program did not improve adherence to apixaban among patients with atrial fibrillation (AF) compared to usual information about the disease and treatment.
News
AHA: Concentrates Promising for Reversal of Apixaban
Different factor concentrates can reverse some of the alterations in hemostasis attributed to apixaban.
News
Prophylaxis With Apixaban Feasible for Cancer Patients
Primary venous thromboembolism prophylaxis with apixaban, an oral direct Factor Xa inhibitor, in ambulatory cancer patients undergoing first- or second-line chemotherapy for advanced or metastatic cancer, is safe and well tolerated.
News
Apixaban Beats Aspirin for Stroke Prevention in A-Fib
Apixaban is more effective than aspirin in reducing the risk of repeat stroke and systemic embolism in patients with atrial fibrillation (AF) who are unsuitable for vitamin K antagonists (VKA) therapy.
